nach oben

Erschienen in:

01.07.2021 | Clinical study

IL17 inhibitors do not increase risk of IBD versus etanercept

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Use of interleukin 17 inhibitors (IL-17i) in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis does not increase the risk of inflammatory bowel disease (IBD) compared with new use of etanercept, according to findings of a study published in Arthritis and Rheumatology. …

Penso L, et al. Risk of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis initiating interleukin 17 inhibitors: a nationwide population-based study using the French national health data system. Arthritis and Rheumatology : 19 Jul 2021. Available from: URL: http://doi.org/10.1002/art.41923

Titel: IL17 inhibitors do not increase risk of IBD versus etanercept
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-99704-x

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

IL17 inhibitors do not increase risk of IBD versus etanercept

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Dolutegravir-related obesity increases adverse pregnancy outcomes

Alectinib/bosutinib/osimertinib

Prednisolone

Diazepam/phenytoin/thiamine

Multiple drugs

Alglucosidase-alfa